Drug Profile
Interferon gamma-1b - Horizon Therapeutics plc
Alternative Names: Actimmune; IFNγ-1b; Imukin; Interferon-gamma-1b; Recombinant-gamma-interferon; Recombinant-interferon-gamma-1bLatest Information Update: 06 Nov 2023
Price :
$50
*
At a glance
- Originator Genentech
- Developer Fox Chase Cancer Center; Friedreichs Ataxia Research Alliance; Horizon Pharma; Horizon Therapeutics plc; InterMune
- Class Antineoplastics; Antivirals; Interferons; Lymphokines
- Mechanism of Action Immunomodulators; Interferon gamma stimulants; Nervous system modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chronic granulomatous disease; Osteopetrosis
- Phase I/II Breast cancer
- No development reported Hepatitis B; Hepatitis C; Solid tumours
- Discontinued Atopic dermatitis; Cryptococcosis; Friedreich's ataxia; Hepatic fibrosis; Keloids; Mycoses; Non-Hodgkin's lymphoma; Ovarian cancer; Pulmonary fibrosis; Renal cell carcinoma; Systemic scleroderma; Tuberculosis
Most Recent Events
- 20 Feb 2023 H. Lee Moffitt Cancer Center and Research Institute, in collaboration with Horizon Pharma Ireland completes a phase I/II trial in Breast cancer (Combination therapy) in USA (SC) (NCT03112590)
- 14 May 2021 Pooled efficacy data from four trials in Idiopathic pulmonary fibrosis presented at the 117th International Conference of the American Thoracic Society (ATS-2021)
- 27 Apr 2020 Interim safety and efficacy data from a phase II trial in Breast caner presented at the 111th Annual Meeting of the American Association for Cancer Research - I (AACR-2020)